お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
987573

体外式膜型人工肺(ECMO)の世界市場:COVID-19パンデミックと呼吸器疾患の有病率の上昇による急成長

COVID-19 Pandemic and Rising Prevalence of Respiratory Disorders Catapult Growth in Global Extracorporeal Membrane Oxygenation (ECMO) Market

出版日: | 発行: Frost & Sullivan | ページ情報: 英文 81 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.99円
体外式膜型人工肺(ECMO)の世界市場:COVID-19パンデミックと呼吸器疾患の有病率の上昇による急成長
出版日: 2020年12月24日
発行: Frost & Sullivan
ページ情報: 英文 81 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

体外式膜型人工肺(ECMO)療法は、最近のCOVID-19パンデミックにより脚光を浴びています。これは、ウイルス感染による急性呼吸窮迫症候群(ARDS)患者の肺組織に十分な治癒時間を与えながら酸素供給を改善する、救命の重要性によるものです。ECMO療法は、2009年のインフルエンザA(H1N1)の流行後、救命救急医の間で広く受け入れられ始めました。

世界の体外式膜型人工肺(ECMO)市場は、一桁台半ばで徐々に成長すると予想されています。これは、慢性閉塞性肺疾患(COPD)の症例の増加と、心肺状態の回復、移植、または補助人工心臓(VAD)への架け橋としての有益な役割により、主流のECMO療法の採用を背景にしています。ECMOの採用を推進する他の主な要因には、ECMO療法の主要な適応症の発生率の高さ、技術の進歩、および機械的人工呼吸などの従来の療法の結果の悪さなどが挙げられます。

当レポートは、世界の体外式膜型人工肺(ECMO)市場について調査しており、市場の動向や予測、COVID-19の影響、成長および抑制要因、課題や機会、製品・技術・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

StrategicImperative

成長機会分析

  • 市場定義
  • 市場の分析範囲
  • 製品と技術別セグメンテーション
  • 地域別セグメンテーション
  • セグメント別:主な競合
  • 体外式膜型人工肺の利点
  • 体外式膜型人工肺の必要性を推進する主要な衝撃力
  • 市場の成長動向
  • 市場におけるStrategicImperative
  • 市場の成長機会を促進する主な要因
  • 現在の状態(問題)から将来の状態(機会)への移行
  • 競合情勢
  • 市場の主要な成長指標
  • 市場における主要な買収
  • 技術進歩のスナップショット
  • 市場の成長要因
  • 市場の抑制要因
  • 予測の前提条件
  • 収益予測スナップショット
  • 収益予測
  • モダリティ別の収益予測
  • コンポーネント別の収益予測
  • 患者タイプ別の収益予測
  • 地域別の収益予測
  • 収益予測分析
  • 地域動向スナップショット
  • 地域別の収益予測分析
  • 競合環境
  • 収益シェア:市場の主要参入企業
  • 収益シェア分析:市場の主要参入企業
  • 競合環境:主な競合

主要競合のプロファイル

  • Medtronic
  • Getinge (Maquet)
  • LivaNova
  • Terumo
  • Nipro
  • Fresenius Medical Care(Xeniosの買収)
  • その他

成長機会分析:北米

成長機会分析:欧州

成長機会分析:アジア太平洋地域

成長機会ユニバース

  • 成長の機会1:最近のCOVID-19危機からの肯定的な実際の結果と試行結果によるVV ECMOの長期使用に対する需要の強化、および革新の推進
  • 成長の機会2:無機的成長戦略を推進するための統合および高度な回路ソリューションを備えた新しい参入企業の出現
  • 成長の機会3:アジア太平洋地域新興市場の成長見通し

次のステップ

目次
Product Code: K56F-54

Next-generation Devices Improving Survival and Workflow Efficiencies Uncovering New Growth Opportunities

Extracorporeal membrane oxygenation (ECMO) therapy has been in the limelight during the recent COVID-19 pandemic. This was due to its live-saving importance by improving the oxygenation, while providing pulmonary tissues adequate healing time, in patients suffering from acute respiratory distress syndrome (ARDS) caused by the viral infection. However, ECMO therapy had started gaining wider acceptance among critical care physicians post the 2009 influenza A (H1N1) pandemic. The driver was the consecutive generation of clinical trial evidence and multiple research studies proving its benefits to respiratory failure compared to conventional ventilation.

The ECMO market is expected to grow gradually, in mid-single digits. This is in the backdrop of increasing chronic obstructive pulmonary disease (COPD) cases and mainstream ECMO therapy adoption due to its beneficial role as a bridge to recovery, transplant, or ventricular assist device (VAD) for cardiopulmonary conditions. Other major factors driving ECMO adoption are currently low market penetration or installed base, higher incidences of key indications for ECMO therapy, advancements in technology, and poor outcomes from conventional therapies like mechanical ventilation. Survival rates with ECMO therapy have improved due to advancements in simplified circuit designs, specifically in oxygenators and blood pumps to enhance gas exchange, minimize hemolysis, and prevent clotting and bleeding risks; and the introduction of standardized protocols in high-volume ECMO centers with dedicated capabilities.

The market is concentrated with very few established participants, like Medtronic, Getinge, LivaNova and Terumo, along with emerging challengers, like Xenios (Fresenius Medical), Eurosets, Spectrum Medical, and OriGen Biomedical. There are also several disruptive participants, like ALung Technologies and Hemovent, with newly launched products. Established Tier I participants, like Medtronic, Terumo, and Getinge, are competitively positioned in the specialized components space. However, the market is transforming toward offering integrated systems with advanced monitoring capabilities due to greater emphasis on safety, simplification and compactness, and ease of usage. Though the ECMO market has not seen fierce inorganic growth strategies, there have been a few notable ones, like the Fresenius Medical-Xenios deal in 2016, LivaNova-TandemLife deal in 2019, and Abiomed-Breethe deal in 2020.

Key Issues Addressed:

  • What are the main trends in extracorporeal membrane oxygenation (ECMO) therapy?
  • Who are the top market participants in the ECMO market?
  • What is the competitive landscape of the ECMO market?
  • What are the ECMO market's key growth drivers and restraints?
  • How would the ECMO market be in 5 years' time? What are the market forecasts from 2019 to 2025?
  • What are the growth opportunities for the ECMO market?

Table of Contents

Strategic Imperatives

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top Three Strategic Imperatives on the Extracorporeal Membrane Oxygenation Market
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis-Extracorporeal Membrane Oxygenation Market

  • Extracorporeal Membrane Oxygenation Market-Definition
  • Extracorporeal Membrane Oxygenation Market Scope of Analysis
  • Extracorporeal Membrane Oxygenation Market Segmentation by Product and Technology
  • Extracorporeal Membrane Oxygenation Market Segmentation by Region
  • Extracorporeal Membrane Oxygenation Market-Key Competitors by Segment
  • Benefits of Extracorporeal Membrane Oxygenation
  • Key Impact Forces Driving the Need for Extracorporeal Membrane Oxygenation
  • Growth Trends in the Extracorporeal Membrane Oxygenation Market
  • Strategic Imperatives on the Extracorporeal Membrane Oxygenation Market
  • Key Factors Driving Growth Opportunity in the Extracorporeal Membrane Oxygenation Market
  • Transition from Current State (Issues) to Future State (Opportunities)
  • Extracorporeal Membrane Oxygenation Market-Competitive Landscape
  • Key Growth Metrics for the Extracorporeal Membrane Oxygenation Market
  • Key Acquisitions in the Extracorporeal Membrane Oxygenation Market
  • Snapshot of Extracorporeal Membrane Oxygenation Technology Advancements
  • Growth Drivers for the Extracorporeal Membrane Oxygenation Market
  • Growth Restraints for the Extracorporeal Membrane Oxygenation Market
  • Forecast Assumptions-Extracorporeal Membrane Oxygenation Market
  • Revenue Forecast Snapshot-Extracorporeal Membrane Oxygenation Market
  • Revenue Forecast-Extracorporeal Membrane Oxygenation Market
  • Revenue Forecast by Modality-Extracorporeal Membrane Oxygenation Market
  • Revenue Forecast by Component-Extracorporeal Membrane Oxygenation Market
  • Revenue Forecast by Patient Type-Extracorporeal Membrane Oxygenation Market
  • Revenue Forecast by Region-Extracorporeal Membrane Oxygenation Market
  • Revenue Forecast Analysis-Extracorporeal Membrane Oxygenation Market
  • Revenue Forecast Analysis-Extracorporeal Membrane Oxygenation Market (continued)
  • Revenue Forecast Analysis-Extracorporeal Membrane Oxygenation Market (continued)
  • Regional Trends Snapshot-Extracorporeal Membrane Oxygenation Market
  • Revenue Forecast Analysis by Region-Extracorporeal Membrane Oxygenation Market
  • Competitive Environment-Extracorporeal Membrane Oxygenation Market
  • Revenue Share-Top Participants of Extracorporeal Membrane Oxygenation Market
  • Revenue Share Analysis-Top Participants of Extracorporeal Membrane Oxygenation Market
  • Competitive Environment-Key Competitors: Extracorporeal Membrane Oxygenation Market

Key Competitor Profiles-Extracorporeal Membrane Oxygenation Market

  • Medtronic
  • Getinge (Maquet)
  • LivaNova
  • Terumo
  • Nipro
  • Fresenius Medical Care (acquired Xenios)
  • Other Emerging Competitors-Extracorporeal Membrane Oxygenation Market

Growth Opportunity Analysis-Extracorporeal Membrane Oxygenation Market: NA

  • Key Growth Metrics for Extracorporeal Membrane Oxygenation Market-NA
  • Revenue Forecast for Extracorporeal Membrane Oxygenation Market-NA
  • Revenue Forecast by Modality for Extracorporeal Membrane Oxygenation Market-NA
  • Forecast Analysis for Extracorporeal Membrane Oxygenation Market-NA

Growth Opportunity Analysis-Extracorporeal Membrane Oxygenation Market: EU

  • Key Growth Metrics for Extracorporeal Membrane Oxygenation Market-EU
  • Revenue Forecast for Extracorporeal Membrane Oxygenation Market-EU
  • Revenue Forecast by Modality for Extracorporeal Membrane Oxygenation Market-EU
  • Forecast Analysis for Extracorporeal Membrane Oxygenation Market-EU

Growth Opportunity Analysis-Extracorporeal Membrane Oxygenation Market: APAC

  • Key Growth Metrics for Extracorporeal Membrane Oxygenation Market-APAC
  • Revenue Forecast for Extracorporeal Membrane Oxygenation Market-APAC
  • Revenue Forecast by Modality for Extracorporeal Membrane Oxygenation Market-APAC
  • Forecast Analysis for Extracorporeal Membrane Oxygenation Market-APAC

Growth Opportunity Universe-Extracorporeal Membrane Oxygenation Market

  • Growth Opportunity 1: Positive Actual and Trial Outcomes from Recent COVID-19 Crisis Can Bolster Demand and Drive Innovations for VV ECMO's Long-term Use
  • Growth Opportunity 1: Positive Actual and Trial Outcomes from Recent COVID-19 Crisis Can Bolster Demand and Drive Innovations for VV ECMO's Long-term Use (continued)
  • Growth Opportunity 2: Emergence of New Participants with Integrated and Advanced Circuit Solutions Set to Drive Inorganic Growth Strategy
  • Growth Opportunity 2: Emergence of New Participants with Integrated and Advanced Circuit Solutions Set to Drive Inorganic Growth Strategy (continued)
  • Growth Opportunity 3: Emerging Markets in APAC Showing Promise of Growth Due to Multiple Tailwinds
  • Growth Opportunity 3: Emerging Markets in APAC Showing Promise of Growth Due to Multiple Tailwinds (continued)

Next Steps

  • Your Next Steps
  • Why Frost, Why
  • List of Exhibits
  • List of Exhibits (continued)
  • Legal Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.